Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5
Maxim Group analyst Jason McCarthy initiates coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with a Buy rating and announces Price Target of $3.5.
Stocks · News reference
8-K filing — MIRA PHARMACEUTICALS, INC. (MIRA)
Filed: 2026-09-17 AccNo: 0001493152-26-043051 Size: 241 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MIRA Pharmaceuticals Submits Phase 2a Ketamir‑2 Protocol For CIPN To IRB, Incorporating FDA Feedback And Targeting Q1 2027 Site Initiation
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday?
MIRA Pharmaceuticals (NASDAQ: MIRA) stock jumps as MIRA-55 meets key preclinical study milestones for non-opioid inflammatory pain relief.